Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis
Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F.
Br J Haematol. 2020;190(2):e110-e114.
In this single-centre case series, we report the results of a retrospective real-world analysis of rrCNSL patients treated with either off-label ibrutinib monotherapy or ibrutinib based combination therapy.